Ruxolitinib improves symptoms and quality of life in a patient with systemic mastocytosis

BACKGROUND: Systemic mastocytosis is a clonal myeloproliferative neoplasm associated with constitutional symptoms from mast cell mediated chemical and cytokine release. According to the literature, Ruxolitinib, a JAK1/JAK2 inhibitor, has been shown to reduce symptoms related to proinflammatory cytok...

Descripción completa

Detalles Bibliográficos
Autores principales: Yacoub, Abdulraheem, Prochaska, Lindsey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4743131/
https://www.ncbi.nlm.nih.gov/pubmed/26855781
http://dx.doi.org/10.1186/s40364-016-0056-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4743131/
https://www.ncbi.nlm.nih.gov/pubmed/26855781
http://dx.doi.org/10.1186/s40364-016-0056-5

Ejemplares similares